
Please try another search
Ananda Pharma Plc, together with its subsidiaries, operates as a biopharmaceutical company that develops cannabidiol-based medicine to treat chronic conditions in the United Kingdom and internationally. Its lead product, MRX1, is in Phase 2a feasibility trials for endometriosis-related pain and in a Phase 2 efficacy study to investigate chemotherapy-induced peripheral neuropathy. The company also offers MRX2 and MRX2t, which are cannabinoid-based medicines in Phase 3 clinical trials for refractory epilepsies. In addition, it engages in crop production; growing of vegetables, melons, and roots and tubers; the wholesale of pharmaceutical goods; the development and distribution of health products; and the manufacture of other organic basic and essential oils. The company was formerly known as Ananda Developments Plc and changed its name to Ananda Pharma Plc in December 2024. Ananda Pharma Plc was incorporated in 2018 and is based in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
John Michael Treacy | 43 | 2018 | Independent Non-Executive Director |
Stuart William Piccaver | 53 | 2022 | Non-Executive Director |
Marie Fallon | - | 2024 | Member of Scientific Advisory Board |
Melissa Josephine Sturgess | 59 | 2018 | CEO & Executive Director |
Clive P. Page | 67 | 2023 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review